A 100% French breakthrough innovation project open to the public.
Some medical innovations don’t make much noise… yet they could fundamentally transform how we prevent diseases.
That’s the case with Lovaltech. Born out of French research and labeled Deeptech by Bpifrance.
Today, vaccines against respiratory diseases such as COVID or influenza effectively protect against severe forms.
However, they have a limitation: they generate little immunity at the level of the respiratory mucosa, even though this is the main entry point for viruses.
As a result, even vaccinated individuals can still become infected and contribute to viral circulation.
Lovaltech is developing a new generation of intranasal vaccines, capable of creating immunity directly at the level of these mucosal tissues.
Their lead COVID candidate is already in Phase I/II human trials, with preclinical data published in npj Vaccines (Nature) showing a significant reduction in viral load and transmission.
Beyond this first vaccine, the co-founders of Lovaltech are developing a true technology platform that could be applied to several diseases:
Long COVID
Influenza
Malaria
A promising positioning in a respiratory vaccine market worth more than $60B.
The company is currently raising €5M, with a portion available for Tudigo investors, more than half of which has already been subscribed.
For those who follow these topics:
✔️ asset already in clinical trials
✔️ multi-indication platform
✔️ eligible for the JEI 50 tax incentive scheme
✔️ value-creation strategy based on clinical milestones and licensing agreements with pharmaceutical companies
As always in biotech:
→ High potential, but also a high level of risk, which requires a diversification strategy.